DEVELOPMENT OF A NOVEL THERAPEUTIC FOR MELIOIDOSIS

类鼻疽新疗法的开发

• 批准号: 10710593
• 负责人: M.R.K. (DICKON) ALLEY
• 金额: $ 430.64万
• 依托单位: AN2 THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-20 至 2024-03-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10710593
• 关键词: Advanced Development; Antibiotic Resistance; Burkholderia pseudomallei; Categories; Chemistry; Clinical; Development; Emerging Communicable Diseases; Melioidosis; National Institute of Allergy and Infectious Disease; Pathway interactions; efficacy evaluation; novel therapeutics; pre-clinical; priority pathogen; product development; research and development; safety assessment; therapeutic candidate; therapeutic development

To support the advanced development of a promising candidate therapeutic for NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

支持针对 NIAID A、B 和 C 类优先病原体或新出现的传染病的有前途的候选疗法的高级开发。所支持的研发活动将使候选治疗产品能够通过产品开发途径取得进展，包括临床前和 IND 开发活动、化学优化/开发、GMP 制造以及临床安全性和疗效评估。